Peptide

Retatrutide

Retatrutide (triple GIP/GLP-1/glucagon receptor agonist)

Triple hormone receptor agonist (GIP, GLP-1, glucagon) still in Phase 3. 28.3% weight loss at 80 weeks in TRIUMPH-1, up to 30.3% at 104 weeks. The most potent weight-loss agent studied in this comparison. Not yet approved anywhere.

Editor approved

Summary Could retatrutide become the most effective weight-loss medicine? Show / hide ↓

Retatrutide is a medicine still being tested and is not approved anywhere as of August 2026. It activates three hormone signals that affect appetite, blood sugar, and how the body uses energy. In large late-stage human studies, people taking the highest dose lost an average of 28.3% of their weight after 80 weeks, and a subgroup reached 30.3% after 104 weeks. The studies also improved blood pressure and blood fats, but no trial has yet shown fewer heart attacks or longer life. Safety information is still developing, and its effects on muscle loss are less precisely measured than for tirzepatide.

What this means for you: Retatrutide has very strong weight-loss results, but it remains experimental. There is not enough long-term safety evidence to use or buy it outside a clinical trial.

moderate evidence

Research snapshot Phase 3 complete. Not approved anywhere. BLA planned Q1 2027.

Updated 2026-10-01

Retatrutide is an experimental drug that activates three hormone receptors at once: GLP-1, GIP, and glucagon. In Phase 3 trials with over 5,800 participants, it produced up to 28.3% weight loss at 80 weeks and 30.3% at 104 weeks. These are the largest weight-loss numbers seen in any drug in clinical development. It is not approved anywhere; Eli Lilly plans to submit for FDA approval in early 2027. The main open question is whether it also reduces heart attacks and strokes.

Evidence tierTier 2, Strong human evidence, hard endpoints or biomarkers

Typical doseOnce-weekly subcutaneous injection. Phase 3 dosed at 4 mg, 9 mg, and 12 mg with stepwise dose escalation from 2 mg weekly. Not available outside clinical trials.

SafetyInvestigational. Not approved. Expected to share GLP-1 class gastrointestinal effects (nausea, vomiting, diarrhea). Thyroid C-cell tumor precautions expected pending approval. Exact adverse event rates from Phase 3 not fully disclosed in public sources. Lean mass loss proportion described as similar to other obesity treatments but exact percentage not disclosed.

CategoryTriple GIP/GLP-1/glucagon receptor agonist (incretin peptide)

Last verified2026-08-08

Retatrutide is the most potent weight-loss agent in clinical development among the incretin agonists. It remains investigational and is not approved by any regulator as of August 2026.

The mechanism is the most complex of the four molecules compared here. Retatrutide activates three hormone receptors on a single peptide: GIP, GLP-1, and glucagon. The GIP and GLP-1 components deliver the same incretin effects as tirzepatide (glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, appetite reduction). The glucagon receptor agonism adds a distinct mechanism: increased energy expenditure and hepatic fat oxidation. This triple agonism is designed to produce greater weight loss than dual or single agonists.

Phase 2 data (NCT04881760, 48 weeks) showed up to 24.2% mean weight reduction at 48 weeks. The body composition substudy (N=189, 36 weeks, DXA) measured fat mass reduction of 26.1% (8 mg pooled dose) and 23.2% (12 mg dose) versus 4.5% with placebo. The publication states the proportion of lean mass loss to total weight loss was similar to other obesity treatments, but does not disclose an exact lean-mass percentage. This makes retatrutide's muscle-sparing profile less precisely characterized than tirzepatide's.

Phase 3 results are the strongest in this comparison. TRIUMPH-1 (obesity, 80 weeks with extension to 104 weeks for BMI 35 or higher) showed 28.3% mean weight loss with 12 mg, 25.9% with 9 mg, and 19.0% with 4 mg. The BMI 35 extension subgroup reached 30.3% at 104 weeks. 45.3% of the 12 mg group achieved 30% or greater weight loss. TRIUMPH-4 (obesity with knee osteoarthritis, 68 weeks) showed 28.7% weight loss with 12 mg and 26.4% with 9 mg, with WOMAC pain score reduction of 4.4 to 4.5 points versus 2.4 points placebo. TRIUMPH-2 (type 2 diabetes with obesity, N=1,152, 80 weeks) used 4 mg, 9 mg, and 12 mg doses with escalation from 2 mg.

No completed cardiovascular outcomes trial exists. TRIUMPH-1 reported significant improvements in cardiovascular risk factors: waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP). These are risk-factor changes, not adjudicated cardiovascular event outcomes.

Safety data is still emerging. As a triple agonist acting through the GLP-1 receptor pathway, retatrutide is expected to share class gastrointestinal effects (nausea, vomiting, diarrhea). Thyroid C-cell tumor precautions would be expected pending final FDA labeling upon approval.

For longevity, the glucagon receptor agonism adds energy expenditure and hepatic fat oxidation mechanisms not present in semaglutide or tirzepatide. The hsCRP reduction in TRIUMPH-1 suggests anti-inflammatory effects. The WOMAC pain reduction in TRIUMPH-4 suggests joint-load reduction or anti-inflammatory effects relevant to healthspan in osteoarthritis. The 30.3% weight loss approaches bariatric surgery levels, but also carries the largest absolute lean-mass loss risk in absolute terms, even if the lean-to-fat loss ratio is comparable to other obesity therapies.

Related in the encyclopedia

Further reading